Search
Indium In-111 oxyquinoline Drug Metabolism
smpdb.ca/view/SMP0130676MetabolicIndium In-111 oxyquinoline is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. … Indium In-111 oxyquinoline passes through the liver and is then excreted from the body mainly through the kidney.
Drugs: Indium In-111 oxyquinolineFatty Acid Elongation in Mitochondria
smpdb.ca/view/SMP0000054MetabolicIn liver and kidney fatty acid elongation operates best in the presence of both NADH and NADPH, whereas in heart and skeletal muscle, only NADH is required. … Mitochondrial elongation may result in fatty acids up to C16 in length. Fatty acid elongation in mitochondria is essentially the reverse of beta-oxidation for fatty acid oxidation.
Indium In-111 pentetate Drug Metabolism
smpdb.ca/view/SMP0130595MetabolicIndium In-111 pentetate is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. … Indium In-111 pentetate passes through the liver and is then excreted from the body mainly through the kidney.
Drugs: Indium In-111 pentetateFc Epsilon Receptor I Signaling in Mast Cells
smpdb.ca/view/SMP0000358SignalingFc epsilon receptor 1 (Fc epsilon RI) is a high-affinity receptor for the Fc region of immunoglobulin E (IgE), an antibody isotope involved in allergies. … This activates the mast cells and results in degranulation, a process by which preformed granules containing histamine, proteoglycans, and serine proteases, are released.
The Oncogenic Action of L-2-Hydroxyglutarate in Hydroxyglutaric aciduria
smpdb.ca/view/SMP0002358DiseaseL-2-hydroxyglutarate is a competitive inhibitor of 2OG-dependent dioxygenases resulting in genetic changes and malignancies. … This results in modulations of HIF-mediated hypoxia responses and alterations in gene expression through global epigenetic remodelling that may contribute to malignant transformation.
The Oncogenic Action of D-2-Hydroxyglutarate in Hydroxyglutaric aciduria
smpdb.ca/view/SMP0002359DiseaseA mutation in IDH causes high concentrations of D-2-Hydroxyglutaric acid. D-2-hydroxyglutarate is a competitive inhibitor of 2OG-dependent dioxygenases resulting in genetic changes and malignancies. … Hydroxyglutaric aciduria is a rare genetic disorder. Both isoforms are believed to have autosomal recessive inheritance.
Homocystinuria-Megaloblastic Anemia Due to Defect in Cobalamin Metabolism, cblG Complementation Type
smpdb.ca/view/SMP0000570DiseaseIt is caused by a mutation in the MTR gene which encodes the enzyme methionine synthase. … Homocystinuria-megaloblastic anemia due to defect in cobalamin metabolism, cblG complementation type, also known as methionine synthase deficiency or methylcobalamin deficiency, cblG type, is a rare inborn
Drugs: Pyridoxal phosphate · Tetrahydrofolic acid · Ademetionine · Choline · Adenosine phosphate · Serine +17 moreHomocystinuria-Megaloblastic Anemia Due to Defect in Cobalamin Metabolism, cblG Complementation Type
smpdb.ca/view/SMP0125684DiseaseIt is caused by a mutation in the MTR gene which encodes the enzyme methionine synthase. … Homocystinuria-megaloblastic anemia due to defect in cobalamin metabolism, cblG complementation type, also known as methionine synthase deficiency or methylcobalamin deficiency, cblG type, is a rare inborn
Drugs: Pyridoxal phosphate · Tetrahydrofolic acid · Ademetionine · Choline · Adenosine phosphate · Serine +17 moreLong-Chain-3-Hydroxyacyl-CoA Dehydrogenase Deficiency (Fatty Acid Elongation in Mitochondria)
smpdb.ca/view/SMP0125748DiseaseMCADD is an autosomal recessive disorder associated with a mutation in the enzyme known as hydroxyacyl-CoA dehydrogenase (HADHA). … The estimated birth prevalence of LCHADD is 1 in 62 000 in Northern European individuals. The worldwide birth prevalence is estimated at 1 in 250 000.
Simvastatin Action Pathway
smpdb.ca/view/SMP0000082Drug actionCytochrome P450 (CYP) enzymes, CYP3A4, CYP3A5, and CYP2C8, have been implicated in this activation step; CYP3A4/5 are responsible for ≥ 80% of simvastatin metabolism while CYP2C8 (not shown in pathway) … The simvastatin hydroxy acid inhibits cholesterol synthesis via the mevalonate pathway by competitively inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase.
Drugs: Cholecalciferol · ATP · Simvastatin · Magnesium cation · Iron · Dimethylallyl Diphosphate +9 moreEnzymes: 3-Hydroxy-3-methylglutaryl-coenzyme A reductase